Asset Management One Co. Ltd. Grows Position in Pfizer Inc. $PFE

Asset Management One Co. Ltd. raised its position in shares of Pfizer Inc. (NYSE:PFE) by 8.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,731,208 shares of the biopharmaceutical company’s stock after acquiring an additional 201,962 shares during the period. Asset Management One Co. Ltd.’s holdings in Pfizer were worth $69,591,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Alpha Omega Wealth Management LLC raised its stake in Pfizer by 8.7% during the third quarter. Alpha Omega Wealth Management LLC now owns 206,264 shares of the biopharmaceutical company’s stock valued at $5,256,000 after purchasing an additional 16,527 shares in the last quarter. Fifth Third Wealth Advisors LLC increased its holdings in shares of Pfizer by 2.5% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 148,737 shares of the biopharmaceutical company’s stock worth $3,790,000 after buying an additional 3,696 shares during the last quarter. Woodward Diversified Capital LLC raised its position in shares of Pfizer by 1.7% during the 3rd quarter. Woodward Diversified Capital LLC now owns 29,549 shares of the biopharmaceutical company’s stock valued at $753,000 after buying an additional 494 shares in the last quarter. DMKC Advisory Services LLC lifted its holdings in shares of Pfizer by 5.3% in the 3rd quarter. DMKC Advisory Services LLC now owns 72,697 shares of the biopharmaceutical company’s stock valued at $1,852,000 after acquiring an additional 3,677 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC grew its position in Pfizer by 4.3% in the third quarter. Moss Adams Wealth Advisors LLC now owns 28,118 shares of the biopharmaceutical company’s stock worth $716,000 after acquiring an additional 1,167 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Up 1.1%

NYSE:PFE opened at $25.17 on Friday. The company has a market cap of $143.13 billion, a price-to-earnings ratio of 14.64 and a beta of 0.47. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The stock has a fifty day simple moving average of $25.18 and a 200-day simple moving average of $24.91.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The company had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s payout ratio is currently 100.00%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: BMO Capital reaffirmed an Outperform rating and a $30 price target, citing Pfizer’s cost controls and a cautious-but-manageable 2026 outlook — a clear vote of confidence for investors focused on valuation and income. BMO reaffirmation
• Positive Sentiment: Multiple bullish analyst/publication pieces argue Pfizer is undervalued and that its pipeline plus deal-making (Seagen, recent obesity-related buys) position it to recover over time — supporting a value-oriented rally. See Fool’s take on medium-term upside. 2 Predictions for Pfizer in 2026
• Positive Sentiment: Analysts at Zacks raised certain near-term quarterly EPS estimates (Q2 2026/Q2 2027), which can help sentiment around upcoming reports and show some upside to consensus in select periods.
• Neutral Sentiment: In-depth pieces (Seeking Alpha, Yahoo Finance) frame 2026 as a “reset” year: higher R&D and acquisition-driven repositioning (notably the Metsera deal) should strengthen Pfizer’s obesity and oncology lineup, but benefits may take time to show. Pfizer 2026: The Reset Year Why Wall Street Gave Up on Pfizer
• Neutral Sentiment: Market commentary reiterates Pfizer’s cheap forward valuation versus peers and highlights that recent M&A (Seagen, Metsera) is beginning to add revenue and late‑stage assets — a longer‑term positive but not immediate earnings relief.
• Negative Sentiment: Pfizer disclosed a death in a long‑term Hympavzi study after a thrombotic stroke — a safety event that could weigh on that program’s outlook and near‑term sentiment. Hympavzi study death
• Negative Sentiment: Analyst estimate trims and management comments point to earnings pressure from the post‑COVID revenue decline and dilution from acquisitions; Zacks trimmed a Q4 EPS estimate — reinforcing near‑term earnings uncertainty.

Wall Street Analyst Weigh In

PFE has been the topic of a number of recent research reports. Cowen restated a “hold” rating on shares of Pfizer in a research report on Tuesday. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $30.00 price objective on shares of Pfizer in a research note on Friday, October 31st. Morgan Stanley cut their price objective on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Friday, December 12th. Finally, Citigroup assumed coverage on shares of Pfizer in a report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $28.06.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.